인터페론 : 시장 인사이트, 경쟁 구도, 시장 예측(-2032년)

Interferon Market by Type (Alpha, Beta, and Gamma), Application (Hepatitis B, Hepatitis C, Leukemia, Multiple Sclerosis, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of chronic and infectious diseases and improved production of interferons.

The interferon market was valued at USD 9,736.63 million in 2024, growing at a CAGR of 4.55% during the forecast period from 2025 to 2032 to reach USD 13,843.44 million by 2032. The demand for interferon is primarily being boosted by the rising prevalence of chronic and infectious diseases. Additionally, improved production of interferons and growing research and development of novel interferon therapies are some of the factors that are contributing to the growth of the interferon market during the forecast period from 2025 to 2032.

Interferon Market Dynamics:

According to GLOBOCAN 2022, approximately 19.98 million people were estimated to be affected by various oncological disorders in 2022. In addition, data from the World Health Organization (WHO) indicated that around 304 million individuals worldwide were living with chronic viral infections, specifically hepatitis B and hepatitis C, during the same year.

Interferons (IFNs), a class of cytokines with antiviral, antiproliferative, and immune-modulating properties, play a pivotal role in managing chronic diseases, including hepatitis B, hepatitis C, multiple sclerosis, and certain cancers (e.g., melanoma). Consequently, the rising prevalence of chronic and infectious diseases, particularly hepatitis and oncological conditions, is projected to drive the demand for interferon therapies throughout the forecast period of 2025 to 2032.

Another key growth driver for the interferon market is the intensifying research and development (R&D) of innovative interferon-based treatments. Ongoing studies are expanding the application of interferons in oncology, particularly in combination therapies with immune checkpoint inhibitors (such as PD-1 and PD-L1 blockers), thereby enhancing their effectiveness against a wider spectrum of cancers. Furthermore, increased collaborations among pharmaceutical companies, research institutions, and biotechnology firms are fostering advancements in novel formulations, improved drug delivery systems, and synergistic combination therapies. These partnerships are pivotal in accelerating the development of more targeted and efficacious interferon-based treatments, thereby broadening market opportunities and improving patient outcomes.

Additionally, both governmental and private sector investments are fueling research into interferon therapies for emerging viral infections and rare diseases, contributing to a robust pipeline of new drug candidates. As these novel therapies progress to commercial availability, they are expected to further propel market expansion.

Despite these promising growth factors, the interferon market faces challenges. Adverse side effects associated with interferon therapies and the availability of alternative treatment options are significant constraints that could potentially hinder market growth during the forecast period.

Interferon Market Segment Analysis:

Interferon Market by Type (Alpha, Beta, and Gamma), Application (Hepatitis B, Hepatitis C, Leukemia, Multiple Sclerosis, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of the interferon market, the leukemia category is projected to capture a significant revenue share in 2024. This growth can be attributed to the extensive use of interferon therapy in leukemia treatment, particularly for certain chronic forms.

Interferon-alpha plays a well-established role in the management of chronic myeloid leukemia (CML), especially in cases where other treatment options, such as tyrosine kinase inhibitors (TKIs), are not well tolerated or contraindicated. Additionally, interferon therapy is considered a standard treatment for hairy cell leukemia (HCL) a rare form of chronic leukemia where it has demonstrated effectiveness in inducing long-term remissions in patients.

The increasing global incidence of leukemia, particularly chronic forms like CML, further contributes to the rising demand for interferon therapies. This trend is driven by factors such as:

• An aging population, which is more susceptible to hematologic malignancies
• Advancements in diagnostic capabilities, leading to earlier and more accurate detection
• Improved awareness and access to healthcare services, facilitating timely treatment

Given these factors, the leukemia segment is expected to witness robust growth during the forecast period, thereby driving the overall expansion of the interferon market.

North America is expected to dominate the overall interferon market:

North America is projected to account for the largest share of the interferon market in 2024. This dominance can be attributed to several key factors, including the rising prevalence of chronic and infectious diseases, robust research and development (R&D) efforts, a well-established healthcare infrastructure, and a favorable regulatory environment that supports product launches and approvals.

According to the American Cancer Society (2023), approximately 1.9 million new cancer cases were diagnosed in the United States in 2023. Furthermore, data from the Centers for Disease Control and Prevention (CDC, 2023) estimated that around 880,000 individuals in the U.S. were living with chronic, long-term hepatitis B as of 2020. The increasing burden of chronic and infectious disorders is expected to fuel the demand for interferon therapies in the U.S., thereby driving the overall market growth in the North American region during the forecast period.

Additionally, the region benefits from ongoing advancements in interferon-related R&D, alongside a strong pipeline of product launches and regulatory approvals. Such developments further accelerate market expansion. For instance, in November 2021, PharmaEssentia Corporation received approval from the U.S. Food and Drug Administration (FDA) for BESREMi(R) (ropeginterferon alfa-2b-njft) for treating adults with polycythemia vera (PV) a significant milestone in expanding therapeutic options within the interferon space.

In summary, the combination of a high disease burden, innovative R&D landscape, advanced healthcare infrastructure, and favorable regulatory policies makes North America a leading market for interferon therapies throughout the forecast period.

Interferon Market Key Players:

Some of the key market players operating in the interferon market include Bayer AG, Amega Biotech, Biogen, Merck KGaA, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Biosidus, AOP Orphan Pharmaceuticals GmbH, Reliance Life Sciences, and others.

Recent Developmental Activities in the Interferon Market:

• In September 2022, Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications with the U.S. Food and Drug Administration (FDA).
• In June 2022, AOP Health presented the final results of Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hematology Association) 2022 Annual Meeting by Professor Heinz Gisslinger, Medical University of Vienna, Austria.

Key Takeaways from the Interferon Market Report Study

• Market size analysis for current interferon market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the interferon market.
• Various opportunities available for the other competitors in the interferon market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current interferon market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for interferon market growth in the coming future?

Target Audience Who Can Be Benefited From This Interferon Market Report Study

• Interferon product providers
• Research organizations and consulting companies
• Interferon-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in interferon
• Various end-users who want to know more about the interferon market and the latest technological developments in the interferon market.

Frequently Asked Questions for the Interferon Market:

1. What are Interferons?

• Interferons (IFNs) are a group of signaling proteins produced and released by host cells in response to the presence of pathogens, such as viruses, bacteria, or tumor cells. They are part of the body's immune response and play a crucial role in fighting infections and regulating the immune system.

2. What is the market for interferons?

• The interferon market was valued at USD 9,736.63 million in 2024, growing at a CAGR of 4.55% during the forecast period from 2025 to 2032 to reach USD 13,843.44 million by 2032.

3. What are the drivers for the global interferon market?

• The demand for interferon is primarily being boosted by the rising prevalence of chronic and infectious diseases. Additionally, improved production of interferons and growing research and development of novel interferon therapies are some of the factors that are contributing to the growth of the interferon market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global interferon market?

• Some of the key market players operating in the interferon market include Bayer AG, Amega Biotech, Biogen, Merck KGaA, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Biosidus, AOP Orphan Pharmaceuticals GmbH, Reliance Life Sciences, and others.

5. Which region has the highest share in the global interferon market?

• North America is expected to dominate the overall interferon market during the forecast period, 2025 to 2032. This is due to the growing prevalence of chronic and infectious disorders in the region. Additionally, growing research and development of novel interferon therapies in the region, the presence of sophisticated healthcare infrastructure, and a viable market in terms of product launch and approval are some of the key factors driving the growth of the interferon market in North America.

Table of Contents

1. Interferon Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Interferon Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Interferon Market Key Factors Analysis

• 5.1. Interferon Market Drivers
  • 5.1.1. Rising prevalence of chronic and infectious diseases
  • 5.1.2. Improved production of interferons
  • 5.1.3. Growing research and development of novel interferon therapies
• 5.2. Interferon Market Restraints and Challenges
  • 5.2.1. Side effects associated with interferon therapies
  • 5.2.2. Availability of alternative therapies
• 5.3. Interferon Market Opportunities

5.3.1.

6. Interferon Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Interferon Market Assessment

• 7.1. By Type
  • 7.1.1. Alpha
  • 7.1.2. Beta
  • 7.1.3. Gamma
• 7.2. By Application
  • 7.2.1. Hepatitis B
  • 7.2.2. Hepatitis C
  • 7.2.3. Leukemia
  • 7.2.4. Multiple Sclerosis
  • 7.2.5. Others
• 7.3. By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Interferon Market Size in USD million (2022-2032)
    • 7.4.1.2. Canada Interferon Market Size in USD million (2022-2032)
    • 7.4.1.3. Mexico Interferon Market Size in USD million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Interferon Market Size in USD million (2022-2032)
    • 7.4.2.2. Germany Interferon Market Size in USD million (2022-2032)
    • 7.4.2.3. United Kingdom Interferon Market Size in USD million (2022-2032)
    • 7.4.2.4. Italy Interferon Market Size in USD million (2022-2032)
    • 7.4.2.5. Spain Interferon Market Size in USD million (2022-2032)
    • 7.4.2.6. Rest of Europe Interferon Market Size in USD million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Interferon Market Size in USD million (2022-2032)
    • 7.4.3.2. Japan Interferon Market Size in USD million (2022-2032)
    • 7.4.3.3. India Interferon Market Size in USD million (2022-2032)
    • 7.4.3.4. Australia Interferon Market Size in USD million (2022-2032)
    • 7.4.3.5. South Korea Interferon Market Size in USD million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Interferon Market Size in USD million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Interferon Market Size in USD million (2022-2032)
    • 7.4.4.2. Africa Interferon Market Size in USD million (2022-2032)
    • 7.4.4.3. South America Interferon Market Size in USD million (2022-2032)

8. Interferon Market Company and Product Profiles

• 8.1. Bayer AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Amega Biotech
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Biogen
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Merck KGaA
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Novartis AG
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Pfizer Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. F. Hoffmann-La Roche Ltd.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Biosidus
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. AOP Orphan Pharmaceuticals GmbH
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Reliance Life Sciences
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. 3SBio Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. CinnaGen Co.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us